* Bicycle Therapeutics PLC BCYC.OQ reported a quarterly
adjusted
loss of 74 cents per share for the quarter ended September 30,
higher than the same quarter last year, when the company
reported EPS of $-1.26. The mean expectation of
thirteen analysts for the quarter was for a loss of 78 cents per
share. Wall Street expected results to range from $-1.05 to -54
cents per share.
* Revenue fell 50% to $2.68 million from a year ago;
analysts
expected $6.84 million.
* Bicycle Therapeutics PLC's reported EPS for the quarter
was a
loss of 74 cents.
* The company reported a quarterly loss of $50.8 million.
* Bicycle Therapeutics PLC shares had risen by 6.2% this
quarter and gained 32.9% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had risen by
about 33.3%
in the last three months.
* In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 11 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"
Wall Street's median 12-month price target for Bicycle
Therapeutics PLC is 38.00
This summary was machine generated from LSEG data November 1 at
03:42 a.m. UTC. All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Sep. 30 2024 -0.78 -0.74 Beat
Jun. 30 2024 -1.10 -0.77 Beat
Mar. 31 2024 -1.24 -0.62 Beat
Dec. 31 2023 -1.23 -1.16 Beat